Gilead Sciences Inc.
Gilead Sciences to Acquire Arcellx for $7.8 Billion
Summary
Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx, Inc. for a total value of $7.8 billion, payable at closing. The transaction includes $115 per share in cash and one contingent value right of $5 per share, contingent upon the achievement of certain sales milestones. The acquisition aims to accelerate the development and commercialization of Arcellx's anito-cel, an investigational CAR T-cell therapy for multiple myeloma. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including regulatory approvals.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement